PD-1 inhibitors have revolutionized the treatment of several cancers, including melanoma and lung cancer, but some patients don’t respond to them. HDAC inhibitors are approved to treat some blood ...

Though there are four histone deacetylase (HDAC) inhibitors that are FDA approved to treat some forms of lymphoma, there’s less evidence for their efficacy in solid tumors. Now, new findings in mice ...

A group of researchers, led by scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has shown that histone deacetylase (HDAC) inhibitors have the ...

Checkpoint inhibitors play a critical role in immunotherapy. Unfortunately, they don’t work all the time. For reasons that have been largely unknown, some patients respond to checkpoint inhibitor ...

A beleaguered class of epigenetic modulators continues to struggle for oncology success, but new insights into their mechanisms in cancer may yet offer hope. In February the US Food and Drug ...

As gene regulation changes in Alzheimer’s disease, scientists believe that histone deacetylases (HDACs) go into overdrive, shutting down transcription of certain genes. Consequently, several research ...

Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced the ...

Preclinical studies suggest that blocking histone deacetylases, which modulate gene transcription, could potentially treat neurodegeneration, but in practice, the theory has not lived up to its ...

Pancreatic cancer is one of the deadliest cancers - only about one in eight patients survives five years after diagnosis. Those dismal statistics are in part due to the thick, nearly impenetrable wall ...